Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors
Article first published online: 28 JUN 2008
Journal of Veterinary Internal Medicine
Volume 18, Issue 2, pages 219–222, March 2004
How to Cite
Poirier, V.J., Hershey, A.E., Burgess, K.E., Phillips, B., Turek, M.M., Forrest, L.J., Beaver, L. and Vail, D.M. (2004), Efficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors. Journal of Veterinary Internal Medicine, 18: 219–222. doi: 10.1111/j.1939-1676.2004.tb00164.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Revised September 19, 2003 Accepted October 7, 2003.
- Malignant histiocytosis;
- Mammary carcinoma;
Paclitaxel (Taxol ®) was administered to 25 dogs with histologically confirmed malignant tumors at a dosage of 165 mg/m2 IV over 3–6 hours every 3 weeks. Dogs received premedication with antihistimines and corticosteroids to reduce hypersensitivity reactions. However, 64% of the dogs still experienced allergic reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant histiocytosis [1 dog]) for a median duration of 53 days. The overall toxicity was unacceptable at the 165 mg/m2 dose. Therefore, subsequent evaluations of paclitaxel in tumor-bearing dogs should a starting dose of 132 mg/ m2 IV every 3 weeks.